The Food Edge Podcast

Somewhere in North America, a consumer is sitting in a NECTAR booth tasting her seventh coded sample of the afternoon. She scores it zero to nine for acceptability and writes one sentence about texture. What she is doing is the most serious consumer sensory work in alt-protein. What the booth does not see is whether she ever buys the product again. This episode argues that the industry has been re...

In 2021, two precision fermentation companies raised on similar promises. Vivici closed a thirty-two point five million euro Series A, backed by dsm-firmenich and Fonterra. Believer Meats raised over three hundred and forty million dollars and achieved regulatory clearance in the United States. Four years later, only one of them can still point to a document that would survive an outside audit. Th...

The ultra-processed foods debate is no longer only a nutrition argument. It is infrastructure. WHO formally initiated guideline work on UPF consumption in 2025. FDA and USDA launched a joint process to build a uniform federal definition. The moment institutions create language, markets start using it as a shortcut. And shortcuts reprice categories before science fully settles them. This episode br...

Japan’s recent FoodTech upgrade is not a public relations moment. It is a structural signal. By naming FoodTech a national strategic sector alongside artificial intelligence and semiconductors, Japan has flipped the order of innovation: policy first, infrastructure second, evidence third, narrative last. This episode breaks down what that sequencing means for founders and investors. We analyse Jap...

Food as Medicine 3.0 marks a structural shift, not a trend. Appetite-suppressing GLP-1 drugs, AI-driven multi-omics, and tightening regulation are forcing food to behave less like lifestyle branding and more like pharmaceutical infrastructure. This episode breaks down how drug-led appetite control is already reshaping food demand, shrinking calorie intake, and pushing brands toward nutrient densit...

Every year, investors tell me they wish they had found certain companies earlier. Not the obvious ones everyone chased. The quiet ones that compounded. The difference between early identification and late discovery is not better prediction about technology breakthroughs. It is not insider access to deal flow. It is knowing which questions to ask and understanding what the answers actually reveal....

GLP-1 isn’t a wellness trend. It’s a demand shock disguised as a prescription. Most food companies are treating semaglutide like a reformulation brief, smaller portions, more protein, lighter claims. That’s the comfortable response. It’s also the wrong level of thinking. Because GLP-1 doesn’t just reduce appetite. It changes the state in which people make food decisions. Less urgency. Less impulse...

Something profound happened in Singapore’s biotech district last month that will fundamentally reshape how every food biotechnology company approaches their geographic strategy. While European founders wait 18-36 months for EFSA Novel Food approvals that may never arrive, a precision fermentation startup received Singapore regulatory authorisation in 240 days and immediately began scaling producti...

Something profound happened on the streets of Zurich this week that will fundamentally reshape how every food delivery company approaches their business model. While the headlines focus on the novelty of robot dogs carrying takeout orders, the real story lies in the economic transformation these machines represent and what their deployment signals about the future of last-mile logistics. Just Eat...

Danone has launched Oikos Fusion , a cultured dairy drink developed specifically for people taking GLP-1 weight-loss medications . Initially, this carefully formulated beverage will be available exclusively in the United States , beginning in Walmart stores this August , with a broader distribution scheduled for Target, Kroger and Wakefern in October . As of now, there is no indication of any laun...

Get full access to Food Edge at amadamek.substack.com/subscribe